GLP-1 signaling and the regulation of pancreatic β-cells mass/function

Zimmet, 2006, Introduction: Globalization and the non-communicable disease epidemic, Obesity (Silver Spring)., 14, 1, 10.1038/oby.2006.1 Zimmet, 2001, Global and societal implications of the diabetes epidemic, Nature., 414, 782, 10.1038/414782a Weir, 2004, Five stages of evolving Beta-cell dysfunction during progression to diabetes, Diabetes., 53, S16, 10.2337/diabetes.53.suppl_3.S16 Weir, 2001, Betacell adaptation and decompensation during the progression of diabetes, Diabetes., 50, S154, 10.2337/diabetes.50.2007.S154 Nolan, 2008, The islet beta-cell: fuel responsive and vulnerable, Trends Endocrinol Metab., 19, 285, 10.1016/j.tem.2008.07.006 Butler, 2003, Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes, Diabetes., 52, 102, 10.2337/diabetes.52.1.102 Moller, 2001, New drug targets for type 2 diabetes and the metabolic syndrome, Nature., 414, 821, 10.1038/414821a Drucker, 2006, The biology of incretin hormones, Cell Metab., 3, 153, 10.1016/j.cmet.2006.01.004 Perley, 1967, Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects, J Clin Invest., 46, 1954, 10.1172/JCI105685 Ritzel, 2001, Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance, Diabetes., 50, 776, 10.2337/diabetes.50.4.776 Ranganath, 1996, Attenuated GLP-1 secretion in obesity: cause or consequence?, Gut., 38, 916, 10.1136/gut.38.6.916 Xu, 2007, Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes, Diabetes., 56, 1551, 10.2337/db06-1033 Gutniak, 1992, Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus, N Engl J Med., 326, 1316, 10.1056/NEJM199205143262003 Hansen, 1999, Glucagon-like peptide-1-(7–36)amide is transformed to glucagon-like peptide-1-(9–36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine, Endocrinology, 140, 5356, 10.1210/endo.140.11.7143 Drucker, 2006, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes, Lancet., 368, 1696, 10.1016/S0140-6736(06)69705-5 Nauck, 1993, Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus, J Clin Invest., 91, 301, 10.1172/JCI116186 Kreymann, 1987, Glucagon-like peptide-1 7–36: a physiological incretin in man, Lancet., 2, 1300, 10.1016/S0140-6736(87)91194-9 Fehmann, 1992, Insulinotropic hormone glucagon-like peptide-I(7–37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells, Endocrinology., 130, 159, 10.1210/endo.130.1.1309325 Stoffers, 2000, Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas, Diabetes., 49, 741, 10.2337/diabetes.49.5.741 Buteau, 1999, Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)- cells, Diabetologia, 42, 856, 10.1007/s001250051238 Holz, 1993, Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7–37), Nature., 361, 362, 10.1038/361362a0 Brubaker, 2002, Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors, Receptors Channels, 8, 179, 10.1080/10606820213687 Thorens, 1992, Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1, Proc Natl Acad Sci USA., 89, 8641, 10.1073/pnas.89.18.8641 Thorens, 1993, Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9–39) an antagonist of the receptor, Diabetes, 42, 1678, 10.2337/diab.42.11.1678 Holz, 1995, Activation of a cAMP-regulated Ca(2+)-signaling pathway in pancreatic beta-cells by the insulinotropic hormone glucagon-like peptide-1, J Biol Chem, 270, 17749, 10.1074/jbc.270.30.17749 Kang, 2001, cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic beta-cells, J Physiol, 536, 375, 10.1111/j.1469-7793.2001.0375c.xd Gromada, 1998, Glucagon-like peptide 1 (7–36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling, Diabetes, 47, 57, 10.2337/diab.47.1.57 Bullock, 1996, Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor, Endocrinology, 137, 2968, 10.1210/endo.137.7.8770921 Campos, 1994, Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse, Endocrinology, 134, 2156, 10.1210/endo.134.5.8156917 Heller, 1997, Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas, Diabetes, 46, 785, 10.2337/diab.46.5.785 Tsuboi, 2003, Glucagon-like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 beta-cells, Biochem J, 369, 287, 10.1042/bj20021288 Widmann, 1994, Signal transduction by the cloned glucagon-like peptide-1 receptor: comparison with signaling by the endogenous receptors of beta cell lines, Mol Pharmacol, 45, 1029 Chepurny, 2002, Exendin-4 as a stimulator of rat insulin I gene promoter activity via bZIP/CRE interactions sensitive to serine/threonine protein kinase inhibitor Ro 31–8220, Endocrinology, 143, 2303, 10.1210/endo.143.6.8870 Lawrence, 2002, NFAT regulates insulin gene promoter activity in response to synergistic pathways induced by glucose and glucagon-like peptide-1, Diabetes, 51, 691, 10.2337/diabetes.51.3.691 Skoglund, 2000, Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element, Diabetes, 49, 1156, 10.2337/diabetes.49.7.1156 Buteau, 2001, Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation, Diabetes, 50, 2237, 10.2337/diabetes.50.10.2237 Buteau, 2003, Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor, Diabetes, 52, 124, 10.2337/diabetes.52.1.124 Buteau, 2004, Glucagon-like peptide-1 prevents beta cell glucolipotoxicity, Diabetologia, 47, 806, 10.1007/s00125-004-1379-6 Wang, 2004, Glucagonlike peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells, Diabetologia, 47, 478, 10.1007/s00125-004-1327-5 Trumper, 2000, Integrative mitogenic role of protein kinase B/Akt in beta-cells, Ann N Y Acad Sci, 921, 242, 10.1111/j.1749-6632.2000.tb06972.x Li, 2005, beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1, Diabetes, 54, 482, 10.2337/diabetes.54.2.482 Buteau, 2006, Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic betacell mass, Diabetes, 55, 1190, 10.2337/db05-0825 Wang, 2002, Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice, Diabetologia, 45, 1263, 10.1007/s00125-002-0828-3 Farilla, 2002, Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats, Endocrinology, 143, 4397, 10.1210/en.2002-220405 Li, 2003, Glucagonlike Peptide-1 Receptor Signaling Modulates beta Cell Apoptosis, J Biol Chem, 278, 471, 10.1074/jbc.M209423200 Hui, 2003, Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5’-adenosine monophosphate-dependent protein kinase A- anda phosphatidylinositol 3-kinase-dependent pathway, Endocrinology, 144, 1444, 10.1210/en.2002-220897 Park, 2006, Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function, J Biol Chem, 281, 1159, 10.1074/jbc.M508307200 Jhala, 2003, cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2, Genes Dev, 17, 1575, 10.1101/gad.1097103 Cornu, 2009, Glucagon-like peptide-1 protects beta-cells against apoptosis by increasing the activity of an IGF-2/IGF-1 receptor autocrine loop, Diabetes, 58, 1816, 10.2337/db09-0063 Quoyer, 2010, GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells, J Biol Chem, 285, 1989, 10.1074/jbc.M109.067207 Yusta, 2006, GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress, Cell Metab, 4, 391, 10.1016/j.cmet.2006.10.001 Tsunekawa, 2007, Protection of pancreatic {beta}-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies, J Endocrinol, 193, 65, 10.1677/JOE-06-0148 Meier, 2010, Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?, Diabetes, 59, 1117, 10.2337/db09-1899 Holst, 2007, The physiology of glucagon-like peptide 1, Physiol Rev, 87, 1409, 10.1152/physrev.00034.2006